Using Baitouweng Decoction to treat ulcerative colitis
Official title: Formula-to-Syndrome Effect and Pharmacomicrobiomics Mechanism of Colon Delivery of Baitouweng Decoction for Treating Large Intestine Damp-heat Syndrome of Ulcerative Colitis
Run by The Second Hospital of Nanjing Medical University · NCT06421818 · Data updated 2026-11-12
This study is testing if a traditional herbal remedy called Baitouweng Decoction can help people with ulcerative colitis by trying it in different ways, like taking it by mouth or as an enema, to see which method works best.
Quick facts
| Phase | Phase 2 |
|---|---|
| Study type | Interventional |
| Sex | All |
| Enrollment | 144 (estimated) |
| Sponsor | The Second Hospital of Nanjing Medical University Academic / other |
| Drugs / interventions | radiation |
| Locations | 1 site (Nanjing, Jiangsu) |
| Status | Recruiting |
| Started | May 2024 |
| Main results expected | December 30, 2026 |
| Study ends | December 30, 2026 |
| Registry record updated | May 21, 2024 |
| Trial ID | NCT06421818 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are patients diagnosed with mild to moderate active ulcerative colitis who exhibit symptoms of large intestine damp-heat syndrome.
✕Probably not a fit
Patients with severe ulcerative colitis or those who do not meet the specific syndrome criteria may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This clinical trial investigates the effectiveness of Baitouweng Decoction in treating large intestine damp-heat syndrome associated with ulcerative colitis. It employs a multi-center randomized controlled design to compare the outcomes of three different administration methods: colon transendoscopic entral tubing (TET), rectal enema, and oral intake. The study will analyze changes in fecal calprotectin levels, disease condition, and safety over a treatment period of 10 days, while also examining the microbiome and metabolomic changes associated with the treatment. A total of 144 subjects will be enrolled and divided into treatment and placebo groups to assess the efficacy and underlying mechanisms of the decoction.
Why it matters
Potential benefit: If successful, this study could provide a new effective treatment option for patients suffering from ulcerative colitis.
How similar studies have gone: While the use of Baitouweng Decoction is traditional, this specific approach using colon TET is novel and has not been extensively tested in prior studies.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Patients diagnosed with ulcerative colitis; 2. The patients are in mild to moderate active stage with Mayo score of 3-8. 3. Patients with damp-heat syndrome of large intestine according to TCM syndrome differentiation: according to the expert consensus on integrated traditional Chinese and Western medicine diagnosis and treatment of UC, the main symptoms are diarrhea, mucopurulent and bloody stool, abdominal pain, and tenesmus. Secondary symptoms: anal burning, body heat is not Yang, dry mouth and bitter mouth, short red urine. Tongue pulse: tongue red fur yellow greasy, pulse slippery number. The determination of the above 8 syndromes can be made if there are 2 main symptoms and 1-2 secondary symptoms. The tongue pulse is for reference only. 4. The patients who can tolerate Baitouweng Decoction; 5. The patients who tolerance to colonoscopy and TET; 6. The patients who know and agree to participate in the clinical trial. Exclusion Criteria: 1. The patients are complicated with other diseases that may cause diarrhea, such as infectious colitis, radiation enteritis, Crohn's disease, etc. 2. Patients with heart, brain, lung, liver, kidney and other serious diseases; 3. Patients do not cooperate to complete the clinical trial process; 4. Other cases considered unsuitable for inclusion.
Where it's running
-
Department of Microbiota Medicine & Medical Centre for Digestive Diseases, The Second Affiliated Hospital of Nanjing Medical University
Nanjing, Jiangsu, China Recruiting
Study contacts
- Principal investigator: Faming Zhang, PhD — The Second Hospital of Nanjing Medical University
- Study coordinator: Faming Zhang, PhD
- Email: fzhang@njmu.edu.cn
- Phone: 02558509670
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Innovative Multidisciplinary and Virtual Care for IBD in Pregnancy
This study tests a dedicated IBD pregnancy care model, including a new virtual approach, to see if it improves access and quality of care for pregnant people with Crohn's disease or ulcerative colitis.
-
A Probiotic Approach to Modulating Gut Microbiota in Mild-to-Moderate Ulcerative Colitis
A specific probiotic given rectally will be tested in adults with mild-to-moderate ulcerative colitis to see if it can help manage symptoms.
-
Advanced therapies for moderately to severely active Crohn's disease or ulcerative colitis in adults
This study tests combinations of risankizumab with either trosunilimab or ABBV-701 in adults with moderately to severely active Crohn's disease or ulcerative colitis.
-
Longitudinal Immunophenotyping of People with Inflammatory Bowel Disease
This study will follow adults with Crohn's disease or ulcerative colitis (and some healthy relatives) over three years to see how their immune cells change over time and how genetics and diet relate to their disease.
-
High Protein, High Fiber Diet for Ulcerative Colitis
This study tests a high-protein, high-fiber diet to see if it helps people with ulcerative colitis by meeting protein needs and lowering harmful hydrogen sulfide production in the gut.
-
Ath-063: Testing a new treatment for moderately to severely active ulcerative colitis in patients who have tried other biologics
This study tests ATH-063 to see if it helps people with moderate to severe ulcerative colitis who did not respond to or relapsed after prior biologic therapy.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.